Evidence map›Paper›PMID 28761166›Full record

ArticleScientific reports2017

Anti-centromere antibody exhibits specific distribution levels among anti-nuclear antibodies and may characterize a distinct subset in rheumatoid arthritis.

Nobuo Kuramoto, Koichiro Ohmura, Katsunori Ikari, Koichiro Yano, Moritoshi Furu, Noriyuki Yamakawa, Motomu Hashimoto, Hiromu Ito, Takao Fujii, Kosaku Murakami and 10 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 2 countries.

Nobuo KuramotoDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Koichiro OhmuraDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Katsunori IkariTokyo Woman's Medical University, Tokyo, Japan.
Koichiro YanoTokyo Woman's Medical University, Tokyo, Japan.
Moritoshi FuruDepartment of the Control for Rheumatic Disease, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Noriyuki YamakawaDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Motomu HashimotoDepartment of the Control for Rheumatic Disease, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Hiromu ItoDepartment of the Control for Rheumatic Disease, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Takao FujiiDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Kosaku MurakamiDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Ran NakashimaDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Yoshitaka ImuraDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Naoichiro YukawaDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Hajime YoshifujiDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Atsuo TaniguchiTokyo Woman's Medical University, Tokyo, Japan.
Shigeki MomoharaTokyo Woman's Medical University, Tokyo, Japan.
Hisashi YamanakaTokyo Woman's Medical University, Tokyo, Japan.
Fumihiko MatsudaDepartment of Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Tsuneyo MimoriDepartment of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Chikashi TeraoDepartment of Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. a0001101@kuhp.kyoto-u.ac.jp.
Kyoto University · JPHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-centromere antibody (ACA) is one of the classical anti-nuclear antibody (ANA) staining patterns. However, characteristics of ACA in comparison with the other ANA patterns and clinical features of ACA-positive subjects have not been elucidated. Here, we examined all ANA patterns by indirect immunofluorescence for 859 rheumatoid arthritis (RA) patients. Together with the ANA data of 9,575 healthy volunteers, we compared distributions of the ANA levels. ACA was the only ANA that demonstrated a definite bimodal distribution of levels. ACA showed significantly higher levels than the other ANA staining patterns in both RA and healthy population (p < 0.0001). ACA-positivity was associated with old age and was observed more in females. We further recruited another cohort of 3,353 RA patients and confirmed the findings. ACA was also associated with Raynaud's phenomenon (p = 6.8 × 10

Indexed as

AdultAgedAged, 80 and overAge FactorsAge of OnsetAntibodies, AntinuclearArthritis, RheumatoidAutoantibodiesCase-Control StudiesCentromereFemaleHumansMaleMiddle AgedSex FactorsAntibodies, AntinuclearAutoantibodies

Identifiers

PMID28761166
PMCPMC5537247
OpenAlexW2739216984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.